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The clinical management of chronic lymphocytic leukemia (CLL) patients with fludarabine-resistant disease or tumor cells with 17p deletions remains problematic. 1 High-dose glucocorticoids (HDGCs) are among the most effective treatment approaches for such patients, as well as elderly patients who cannot tolerate conventional chemotherapy. However, HDGCs are not without significant side effects and are only palliative in nature. 2 Identification of nontoxic agents that could improve the therapeutic efficacy of HDGCs would help significantly in managing these patients.
We report a case that suggests the weak androgen Danazol 3 may be such an agent. A 61-year-old female with slowly progressive Rai Stage II CLL, diagnosed 6 years earlier and characterized by the 11q deletion with high CD38 expression (44%), was being considered for first-line chemotherapy on the basis of increased fatigue and lymphocyte doubling time ( Figure 1a ). The patient also had episodal angioedema from an acquired C1 esterase inhibitor deficiency related to CLL. 4 Prior to a dental procedure, her allergist prescribed Danazol 300 mg p.o. b.i.d. for 1 week to raise C1-inhibitor levels in order to prevent possible airway obstruction from oral angioedema. 5 Coincidentally, she was seen in the CLL clinic a week later where her white blood cell (WBC) count had dropped from 76 to 42 Â 10 6 cells/ml ( Figure 1a ) and she reported improvements in subjective symptoms. Another dental procedure was scheduled for the following month and the patient consented to give blood before and after the Danazol-specific death after 48 h for six female and five male patient samples. The P-value for the difference between sample means was calculated using a two-sample t-test.
prophylactic course of Danazol. Remarkably, the WBC count, which had increased in the time off Danazol, decreased significantly again in response to Danazol, although it increased again in the following weeks ( Figure 1a ). Similar declines in circulating WBC counts have been observed in two male patients treated with Danazol (400 mg p.o. b.i.d.) for 2 months (not shown).
This apparent clinical activity of Danazol prompted laboratory studies of its effects on CLL cells. Danazol was found to be toxic to CLL cells above 3 mM (Figure 1b) , although it was generally less toxic than the synthetic glucocorticoid Dexamethasone (Dex) (Figure 1c ). Danazol killed both male and female CLL cells, although the former appeared somewhat more sensitive (Figure 1d ). We considered that Danazol might have off-target effects on the glucocorticoid receptor (GR) to explain its cytotoxic activity against CLL cells. Indeed, Danazol induced phosphorylation of the GR (indicating activation of the receptor) in CLL cells, although it was weaker than Dex (Figure 2a) . However, Danazolmediated killing was not blocked by the GR antagonist Mifepristone, 6 in contrast to Dex (not shown). Consistent with a GR-independent mechanism, Danazol had additive effects on Dexinduced cytotoxicity (Figure 2b) .
We then examined the effects of Danazol specifically on CLL cells with 17p deletions (Figure 2c, bottom left panel) . At a dose of 10 mM, Danazol remained capable of killing such cells, especially in combination with Dex. Compared with CLL cells without this cytotogenetic abnormality, 17p
À tumor cells appeared less sensitive to Danazol, with or without Dex, although the differences were not statistically significant (Figure 2c, right panel) . Note the results for Figure 2c were obtained with cryopreserved cells and the higher levels of spontaneous death following thawing account for the lower specific death levels in comparison with Figure 2b , which were obtained with fresh tumor cells. Although Danazol and low doses of glucocorticoids could potentially compete for the GR, the possibility of combining Danazol with HDGCs is supported by the example of an 85-yearold female with symptomatic Rai Stage IV CLL and trisomy 12 tumor cells. Fludarabine-and alkylator-based regimens were felt to be contraindicated because of the patient's congestive heart failure and she was treated with HDGCs (1500 mg Prednisone PO Â 5 days), 7 but suffered side effects of fluid retention and profound fatigue. On the basis of previous use of Danazol as a steroid-sparing agent in autoimmune disorders, 8 the prednisone dose was lowered to 1000 mg p.o. daily for 4 days and Danazol  (200 mg p.o. b.i.d.) was added to the next two treatment cycles. The treatments were better tolerated and the clinical response was maintained and possibly even enhanced (Figure 2d ).
These observations suggest that Danazol has clinical activity in CLL and can be used safely with HDGCs. Danazol has been prescribed for almost 40 years 3 and has a well-known toxicity profile. It causes virilization in young women with endometriosis, which is not necessarily a problem for older male or postmenopausal female CLL patients. Danazol is otherwise relatively safe but patients must be monitored for thrombosis and lipid and liver abnormalities. 9 Along with its use in autoimmune disorders, 4, 8 Danazol is thought to have activity in myelodysplastic syndromes 3 and can prevent interferon-induced thrombocytopenia. 10 Over 2500 papers on Danazol are listed in PubMED but, to our knowledge, its activity in CLL has not been reported before.
The mechanism of action of Danazol in CLL is not clear. Blood levels of CD23 were lowered by Danazol in endometriosis, 11 suggesting a direct effect on activated B cells, which are considered the normal counterparts of CLL cells. 12 However, we could not detect an effect of Danazol on CD23 expression by CLL cells in vitro (not shown). Danazol has been reported to decrease the production of inflammatory cytokines, including interleukin-6 and tumor necrosis factor-a, which may limit their ability to cause proliferation of CLL cells in vivo.
13
Danazol can also intercalate into cell membranes, 14 which may dysrupt growth-promoting signaling processes and account for a mechanism of action apparently independent of glucocorticoid, estrogen and androgen receptors (Figure 1d ).
The observations reported in this letter suggest clinical trials to determine whether the anti-CLL effect of Danazol can be exploited to improve the clinical efficacy of HDGCs. Conventional oral doses of Danazol have been reported to achieve erythrocyte membrane levels that approach the mM levels that appear to be needed for cytotoxicity (Figures 1 and 2 ). Initial clinical studies will focus on determining whether optimal dosing of Danazol in CLL patients can be achieved through the oral route, 7 or whether i.v. administration will be required. Cytarabine (ara-C) enters cells primarily as a false substrate through specialized nucleoside transporter proteins, predominantly hENT1 (the human equilibrative nucleoside transporter). 1, 2 Reduced hENT1 expression and/or activity is associated with adverse therapeutic outcomes in patients with acute myeloid leukemia (AML) treated with ara-C. 3, 4 Elacytarabine (CP-4055) (Figure 1) , the lipophilic 5 0 -elaidic acid ester of ara-C, enters cells independently of hENT1 and is active in both ara-C-resistant cell lines 5 --7 and animal tumor xenograft models. 8, 9 In patients with
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